New Markers for Colon Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 5
Volume 10
Issue 5

NEW ORLEANS-Colorectal cancer cells are shed into the stool, providing a potential means for early detection using noninvasive approaches. A multi-center research effort has evaluated a set of three genetic markers that may indeed constitute a reliable genetic mutation analysis of stool, signifying cancer

NEW ORLEANS—Colorectal cancer cells are shed into the stool, providing a potential means for early detection using noninvasive approaches. A multi-center research effort has evaluated a set of three genetic markers that may indeed constitute a reliable genetic mutation analysis of stool, signifying cancer.

At the 92nd Annual Meeting of the American Association for Cancer Research, Jin Jen, MD, PhD, presented the report on behalf of investigators from Johns Hopkins, M.D. Anderson, Cornell, Howard Hughes Medical Institute, and the National Cancer Institute.

The study included 51 patients with colorectal cancers for whom paired stool and primary tumor samples were taken. Two complementary methods were developed to isolate stool DNA for robust PCR amplification of human gene fragments, and three genetic targets were used for mutation detection: K-RAS mutations, TP53 mutation (a common p53 mutation in colorectal cancer), and BAT26 deletion.

TP53 gene mutations were detected in the stool of 30 patients, and all of these mutations were confirmed in the primary tumors of these patients. Three of the 51 stool samples contained deletions at the BAT26 locus, and each of these gene alterations was also identified in the corresponding tumor specimen. K-RAS mutations were detected in 17 tumors but in only 8 stool samples; therefore, this component was considered less sensitive than TP53 and BAT26, said Dr. Jen, who recently moved to the NCI Laboratory of Population Genetics.

The 30 TP53 mutations were detected in all stages of cancer and at all sites in the colon. The three BAT26 cases included two Duke’s B tumors and one Duke’s C tumor. All were in the ascending colon. The eight K-RAS mutations in the stool included five Duke’s B and three Duke’s C cancers, and all were in the descending colon.

This study makes clear, Dr. Jen said, that the majority of colorectal cancers can be detected through alterations in the DNA purified from stool using these three genetic markers. The markers jointly detected cancer in 71% of patients with colorectal cancer and in 92% of patients whose tumors had an alteration.

The results lay the groundwork for large prospective studies to determine the sensitivity and specificity of the tests for screening asymptomatic patients.

Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content